Institutional investors hold a majority ownership of NKTR through the 98.40% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended June 2019, these large investors purchased a net $6.6 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 4.4 Million shares of Nektar Therapeutics
FIRST TRUST ADVISORS LP Bought 3.4 Million shares of Nektar Therapeutics
GREAT POINT PARTNERS LLC Bought 3.2 Million shares of Nektar Therapeutics